Global Product Pipeline
Building the best product pipeline in the industry
GlaxoSmithKline Inc. (GSK) is one of the largest research and development (R&D) organizations in Canada. GSK invested more than $118 million in Canadian research and development (R&D) in 2013, ranking it among the top 25 contributors to R&D in Canada, across all industries.
The company's Pharmaceutical Development Division has developed a number of products including: Zofran® syrup and the fast-disintegrating Zofran® ODT tablets for nausea and vomiting associated with chemotherapy and radiotherapy treatments; and Heptovir® tablets for the treatment of hepatitis B.
GlaxoSmithKline's $22 million Pathfinders Fund for Leaders in Canadian Health Science Research was established to help Canada become a world leader in R&D. This initiative encourages health science research and fosters medical innovation in Canadian medical schools.